Microbix Client Labquality Introduces Novel EQA Scheme at ESCV
News Source : Financial Post
News Summary
- Supporting Clinical Labs in Accurately Identifying HPV-associated Head and Neck Cancers.
- Over 300,000 HNCs are diagnosed in North America and Western Europe each year, accounting for approximately 4% of all cancers.
- Until now, no program existed to check the proficiency of clinical labs in such work.
- Microbix created novel FFPE-formatted “QAPs™” mimetics of HNC patient samples – containing both IHC & PCR targets.
Heidi Berghll, EQA Solutions Manager, R&D of Labquality, commented, It is important that both pathology and molecular tests are validated via a proper EQA scheme to monitor ongoing performance. [+4304 chars]
Never miss a story from us, subscribe to our newsletter